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a  b  s  t  r  a  c  t
The  pathogenesis  of frailty  and  the  role of  inﬂammation  is poorly  understood.  We  examined  the  evi-
dence  considering  the  relationship  between  inﬂammation  and  frailty  through  a systematic  review and
meta-analysis.  A systematic  literature  search  of  papers  providing  data  on inﬂammatory  biomarkers  and
frailty was carried  out  in major  electronic  databases  from  inception  until May  2016.  From  1856  ini-
tial  hits,  35  studies  (32  cross-sectional  studies  n = 3232  frail,  n  = 11,483  pre-frail  and  n  =  8522  robust,eywords:
and  563  pre-frail  + robust;  3 longitudinal  studies  n =  3402  participants  without  frailty  at baseline)  werenﬂammation
meta-analyzed.  Cross-sectional  studies  reported  that  compared  to  6757  robust  participants,  both  1698re-frailty
railty
ging
-Reactive protein
nterleukin-6
frail  (SMD  =  1.00,  95%CI:  0.40–1.61)  and  8568  pre-frail  (SMD  = 0.33,  95%CI:  0.04–0.62)  participants  had
signiﬁcantly  higher  levels  of  C-reactive  protein  (CRP).  Frailty  (n  =  1057;  SMD = 1.12,  95%CI:  0.27–2.13)
and  pre-frailty  (n =  4467;  SMD  = 0.56,  95%CI:  0.00–1.11)  were  associated  with  higher  serum  levels  of
interleukin-6  compared  to  people  who  were  robust  (n = 2392).  Frailty  and  pre-frailty  were  also  signiﬁ-
cantly  associated  with  elevated  white  blood  cell  and  ﬁbrinogen  levels.  In  three  longitudinal  studies,  higher
∗ Corresponding author at: University of Padova, Department of Medicine (DIMED)-Geriatrics Section, Via Giustiniani, 2, 35128 Padova, Italy.
E-mail  address: ilmannato@gmail.com (N. Veronese).
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568-1637/© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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serum  CRP  (OR  = 1.06,  95%CI:  0.78–1.44,)  and  IL-6  (OR  =  1.19,  95%CI:  0.87–1.62)  were  not  associated  with
frailty.  In conclusion,  frailty  and  pre-frailty  are  associated  with  higher  inﬂammatory  parameters  and  in
particular  CRP and  IL-6.  Further  longitudinal  studies  are  needed.
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. Introduction
Age-associated decline in reserve and function may  result in a
educed ability to cope with acute or external stressors faced every
ay, which is typically deﬁned as frailty (Clegg et al., 2013). Frailty is
 relevant issue in geriatric medicine, since frailty is associated with
 higher risk of poor outcomes such as falls, depression, disability,
nd mortality (Fried et al., 2001). Frailty is becoming one of the
ost signiﬁcant clinical conditions affecting older people, with a
revalence of 10% for those older than 65 years and 30% for those
lder than 80 years (Fried et al., 2001).
Despite an increase in interest in frailty, the pathophysiological
hanges underlying and preceding frailty are not clearly known.
nﬂammation is one such potential pathophysiological change
hich may  be closely linked with frailty (Chen et al., 2014). Pro-
nﬂammatory cytokines may  inﬂuence frailty either directly by
romoting protein degradation, or indirectly by affecting impor-
ant metabolic pathways (Lang et al., 2009). A direct association
etween frailty and elevated levels of inﬂammation, as marked by
levated interleukin-6 (IL-6), C-reactive protein (CRP), ﬁbrinogen,
nd factor VIII, independent of common chronic disease states has
een observed (Newman et al., 2001). Conversely, other studies
ave found that these markers are not predictive of incident frailty
n the elderly (Yao et al., 2011). Thus, there is a lack of clarity consid-
ring the role and status of inﬂammation in frailty and to the best
f our knowledge, no meta-analysis has attempted to synthesize
he available data on this topic.
Therefore, we conducted a systematic review and meta-analysis
omparing the inﬂammatory proﬁle of frail and pre-frail with and
obust subjects in cross sectional studies. In addition, we  inves-
2. Materials and methods
This systematic review was  conducted according to the
Strengthening the Reporting of Observational Studies in Epi-
demiology [STROBE] criteria (von Elm et al., 2008) and the
recommendations in the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses [PRISMA] statement (Liberati et al.,
2009). This work followed a pre-determined, but unpublished pro-
tocol available upon request.
2.1. Search strategy
Three independent authors (PS, BS and NV) searched Medline
(via Ovid), Psychinfo and EMBASE for studies from inception until
05/2016 without language restrictions. The search terms used were
(frailty OR frail) AND ((“inﬂammation”[MeSH Terms] OR “inﬂam-
mation”[All Fields]) OR inﬂammatory[All Fields] OR IFN [All Fields]
OR (“interferons”[MeSH Terms] OR “interferons”[All Fields] OR
“interferon”[All Fields]) OR TNF [All Fields] OR “tumor necrosis
factor”[All Fields] OR IL[All Fields] OR “interleukin”[All Fields] OR
“TGF”[All Fields] OR (“apoptosis”[MeSH Terms] OR “apoptosis”[All
Fields]) OR apoptotic[All Fields] OR antiapoptotic [All Fields] OR
CRP[All Fields] OR (“cytokines”[MeSH Terms] OR  “cytokines”[All
Fields] OR “cytokine”[All Fields])).
2.2. Study selection
Included studies were those that were published quantitative
studies of a cross sectional or longitudinal design that (1) reportedigated whether or not any inﬂammatory parameters at baseline
ould predict the onset of frailty in prospective studies. Our hypoth-
sis was that both frailty and pre-frailty were associated with
igher pro-inﬂammatory cytokines levels.on serum levels of inﬂammatory parameters, (2) used a validated
and standardized method for assessing frailty, (3) included a con-
trol group (pre-frail and robust as separated entities or together):
(4) used serum inﬂammatory parameters as predictors of frailty
search
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(P. Soysal et al. / Ageing Re
longitudinal design). Studies were excluded if they (1) did not use
 clear diagnostic criteria for frailty or used only one item for its
iagnosis (e.g. low gait speed), (2) measured only in vitro param-
ters, (3) did not measure or did not report quantitative cytokine
evels.
.3. Data extraction
To be included in the quantitative analyses, we required data on
erum inﬂammatory parameters in frail, pre-frail and robust par-
icipants expressed as means ± standard deviation (SD) or median
ith range (or interquartile range).
Two authors (PS, NV) independently extracted data from the
elected studies in a standardized Microsoft Excel spreadsheet.
ny disagreement was resolved by through discussion with a third
uthor (BS). The following information was extracted: (i) charac-
eristics of the study population (e.g. sample size, demographics,
ountry in which the study was performed); (ii) setting in which
he study was performed; (iii) diagnostic criteria for frailty; (iv)
nﬂammatory parameters assessed with correspondent method of
easurement; (v) demographic characteristics (mean age and per-
entage of women) and mean body mass index (BMI) by frailty
tatus; (v) categorization used for dividing the sample in groups by
erum inﬂammatory levels (for longitudinal studies); (vi) type and
umber of adjustments in the multivariate analyses (for longitudi-
al studies); (vi) follow-up period (only for longitudinal studies).
When information on frailty and/or serum inﬂammatory param-
ters was missing, study authors were contacted to obtain
npublished data at least 4 times in a one month period.
.4. Outcomes
The primary outcomes were the serum levels of inﬂammatory
ytokines and parameters in frail vs. pre-frail and robust (as sepa-
ate entities) or vs. pre-frail/robust (as only one group). For incident
railty, the odds ratios (ORs) adjusted for the highest number of
ovariates available, were considered to assess the association
etween serum inﬂammatory parameters and frailty and consid-
red as secondary outcome of our work.
.5. Assessment of study quality
Study quality was assessed by two investigators (PS, PL), whilst a
hird reviewer was available for mediation (NV). For cross-sectional
nd longitudinal studies, the Newcastle-Ottawa Scale (NOS) (Wells
t al., 2012) was used to assess study quality. The NOS assigns a
aximum of 9 points based on three quality parameters: selection,
omparability, and outcome (Wells et al., 2012).
.6. Statistical analysis
Analyses were performed by two independent investigators
NV, EC) using Comprehensive Meta-Analysis (CMA) 3 (http://
ww.meta-analysis.com). All cytokines were meta-analyzed when
3 studies contributed data.
In primary analyses, standardized mean differences (SMDs) and
5% conﬁdence intervals (CI) were calculated. In the secondary
nalyses, the most adjusted pooled HRs were calculated for longitu-
inal analyses. When combining studies, the random effects model
as used to account for anticipated heterogeneity (DerSimonian
nd Laird, 1986).Heterogeneity was measured using the chi-squared and I-
quared statistics, assuming that a p ≤ 0.10 for the former and
 value ≥50% for the latter indicated a signiﬁcant heterogeneity
Higgins and Thompson, 2002). Reviews 31 (2016) 1–8 3
Given signiﬁcant heterogeneity, a meta-regression analysis was
performed using differences in mean age, body mass index (BMI)
and percentage of females among groups (frail, pre-frail, robust)
as moderators. Moreover, a sensitivity analysis was conducted
stratiﬁed by continent in which the study was  performed (North
America, Asia, Europe), setting (community-dwelling vs. hospital),
and deﬁnition of frailty (Fried’s criteria vs. other deﬁnitions).
Publication bias was assessed by visually inspecting funnel plots
and using the Begg-Mazumdar Kendall tau (Begg and Mazumdar,
1994) and the Egger bias test (Egger et al., 1997). To account for
publication bias, we used the trim-and-ﬁll method, based on the
assumption that the effect sizes of all the studies are normally
distributed around the center of a funnel plot; in the event of asym-
metries, it adjusts for the potential effect of unpublished studies
(Egger et al., 1997). Finally, the fail safe number of negative studies
that would be required to nullify (i.e. make p > 0.05) the effect size
was calculated (Rosenthal, 1979).
3. Results
The search identiﬁed 1856 non-duplicated potentially eligible
studies. After excluding papers following a review of titles and
abstracts (mainly being reviews or not related to the association
between frailty and inﬂammation, full details summarized in Sup-
plementary Fig. 1), 66 full-text articles were examined, and 35
studies (32 cross-sectional (Addison et al., 2014; Almeida et al.,
2012; Arts et al., 2015; Barzilay et al., 2007; Brouwers et al., 2015;
Carcaillon et al., 2012; Chao et al., 2015; Collerton et al., 2012;
Comptè et al., 2013; Darvin et al., 2014; Fontana et al., 2013; Gale
et al., 2013; Hubbard et al., 2009; Hwang et al., 2015; Kalyani et al.,
2012; Lai et al., 2014; Leng et al., 2011, 2007, 2004a,b; Liu et al.,
2016; Piggott et al., 2015; Pustavoitau et al., 2016; Qu et al., 2009;
Rønning et al., 2010; Saum et al., 2015; Sergi et al., 2015; Serviddio
et al., 2009; Singer et al., 2015; Tsai et al., 2013; Walston et al.,
2002; Wu et al., 2009) and 3 longitudinal (Baylis et al., 2013; Puts
et al., 2005; Reiner et al., 2009)) were included in our meta-analysis
(Supplementary Fig. 1).
3.1. Study and patient characteristics
Study and patient characteristics of cross-sectional studies are
summarized in Supplementary Table 1.
The 32 cross-sectional studies (Addison et al., 2014; Almeida
et al., 2012; Arts et al., 2015; Barzilay et al., 2007; Brouwers et al.,
2015; Carcaillon et al., 2012; Chao et al., 2015; Collerton et al., 2012;
Comptè et al., 2013; Darvin et al., 2014; Fontana et al., 2013; Gale
et al., 2013; Hubbard et al., 2009; Hwang et al., 2015; Kalyani et al.,
2012; Lai et al., 2014; Leng et al., 2011, 2007, 2004a,b; Liu et al.,
2016; Piggott et al., 2015; Pustavoitau et al., 2016; Qu et al., 2009;
Rønning et al., 2010; Saum et al., 2015; Sergi et al., 2015; Serviddio
et al., 2009; Singer et al., 2015; Tsai et al., 2013; Wu  et al., 2009)
included a total of 23,910 older participants with a mean age of
75.2 ± 6.1 years.
Overall, there were 3332 (=13.9%) frail, 11,483 pre-frail (=48.0%)
and 8532 robust subjects, while 563 additional participants were
classiﬁed as pre-frail/robust.
All of the included studies used a modiﬁed version of Fried et al.
(2001) deﬁnition for frailty, except for ﬁve deﬁned by Frail Scale,
Balducci Score, Modiﬁed Physical Performance Test Score, Identiﬁ-
cation of Seniors At Risk, MPI  (Addison et al., 2014; Brouwers et al.,
2015; Chao et al., 2015; Comptè et al., 2013; Fontana et al., 2013).The majority of the studies were conducted among community-
dwellers (22 studies; = 69%) and in North America (n = 14), followed
by Europe (n = 11), Asia (n = 6) and Oceania (n = 1) (Supplementary
Table 1). The quality of the studies, assessed through NOS, was gen-
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rally good with a median = 7 (range: 4–9) (Supplementary Table
).
Frail participants were older (mean age: 78.1 years), more fre-
uently females (=61.8%) and with higher BMI  (=26.8 kg/m2) than
re-frail (age: 75.4 years; % of females: 58.9; BMI: 26.4 kg/m2),
obust (age: 72.8 years; % of females: 54.6; BMI: 26.3 kg/m2) or pre-
rail/robust (age: 74.8 years; % of females: 58.9; BMI: 25.8 kg/m2)
articipants (Supplementary Table 1).
.2. Cross-sectional meta-analysis ﬁndings
As reported in Table 1, 13 studies (Barzilay et al., 2007; Carcaillon
t al., 2012; Collerton et al., 2012; Fontana et al., 2013; Hubbard
t al., 2009; Hwang et al., 2015; Lai et al., 2014; Liu et al., 2016;
ønning et al., 2010; Saum et al., 2015; Tsai et al., 2013; Walston
t al., 2002; Wu et al., 2009) reported that both frail (SMD = 1.00,
5%CI: 0.40–1.61, p < 0.0001; I2 = 98%) and pre-frail (SMD = 0.33,
5%CI: 0.04–0.62, p = 0.03; I2 = 98%) participants had signiﬁcantly
igher serum levels of CRP. The fail safe number of studies (i.e.,
he number of negative studies required to nullify our result >0.05)
as very high for each of these analyses (see Table 1). Similar ﬁnd-
ngs emerged when comparing frail vs. pre-frail/robust subjects in
 studies (Almeida et al., 2012; Arts et al., 2015; Comptè et al., 2013;
ale et al., 2013) (SMD = 0.25, 95%CI: 0.02–-0.49, p = 0.04; I2 = 81%).
Frailty (SMD = 1.12, 95%CI: 0.27–2.13, p = 0.01; I2 = 99%) and
re-frailty (SMD = 0.56, 95%CI: 0.00–1.11, p = 0.05; I2 = 99%) were
ssociated with higher serum levels of IL-6 versus robust partici-
ants. The fail safe number of studies was 1650 and 1014 for the
railty and pre-frailty analyses, respectively.
Similar results were evident regarding white blood cells and
brinogen levels, while no differences emerged for TNF-alpha
Table 1).
.3. Meta-regression and sensitivity analyses
Since the differences in inﬂammatory parameters between
railty, pre-frailty and robustness were characterized by a high
eterogeneity (I2 ≥ 50%, p < 0.05), where a sufﬁcient number of
tudies were available (at least 4 for each outcome), we  ran a meta-
egression analysis to seek potential moderators.
As shown in Supplementary 2, very few moderators appeared
o explain the heterogeneity present in our analyses. Differences
n age between the frail and robust samples moderated the results
n the comparison between frail vs. pre-frail/robust regarding CRP
beta = −0.08; 95%CI: −0.11 to −0.04, p = 0.0003, R2 = 1.00) and
L-6 (beta = −0.24; 95%CI: −0.40 to −0.08, p = 0.004, R2 = 0.82),
hile higher differences in BMI  between frail (beta = 0.97; 95%CI:
.46–1.49, p = 0.002, R2 = 0.55) or pre-frail (beta = 0.76; 95%CI:
.18–1.35, p = 0.01, R2 = 0.39) vs. robust participants moderated the
esults regarding CRP (Supplementary Table 2).
Supplementary Table 3 shows the results of cross-sectional
tudies according to some strata, namely country in which the
tudy was performed, the setting and the deﬁnition of frailty. Over-
ll, these moderators seem not to signiﬁcantly affect our ﬁndings.
n particular, we found that frailty and pre-frailty were associ-
ted with signiﬁcantly elevated CRP and IL-6 levels across all
eographical settings and among community and institutionalized
articipants (see Supplementary Table 3).
.4. Longitudinal meta-analysis ﬁndingsThree studies (Baylis et al., 2013; Puts et al., 2005; Reiner et al.,
009) followed-up 3402 older participants without frailty at base-
ine for a median of 3 years (range: 3–10) (Supplementary Table
). Ta
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n
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rFig. 1. Relationship between serum C-reactive protein levels (a) and inter
After adjusting for a median of 9 potential confounders (range:
–10), both higher serum CRP (OR = 1.06, 95%CI: 0.78–1.44, p = 0.69,
20%; Fig. 1a) and IL-6 (OR = 1.19, 95%CI: 0.87–1.62, p = 0.27, I20%;
ig. 1b) levels were not associated with higher risk of frailty.
.5. Publication bias
Judging from a visual inspection of funnel plots and using Egger’s
est (Table 1 for cross-sectional studies), no publication bias was
vident for all the outcomes included. A similar absence of publi-
ation bias was present for longitudinal studies, although limited
y the number of studies included.
. Discussion
In this meta-analysis including 32 cross-sectional studies and
3,910 older subjects, we observed that frailty and pre-frailty were
ssociated with signiﬁcantly higher serum inﬂammatory param-
ters compared to robust participants. In particular, we found a
arge increase in CRP and IL-6 in frail and pre-frail participants
ersus robust participants, with very high fail safe number of stud-
es required to nullify these results. The elevated CRP and IL-6
ere consistent across geographical regions and both in commu-
ity and hospital settings. We  also found evidence of elevated white
loods cells and ﬁbrinogen. On the contrary, three large prospective
tudies failed to ﬁnd any association between higher inﬂammatory
evels at baseline and incident frailty. Meta-regression analyses of
he cross-sectional data suggest that age and BMI  moderate the
elationship between CRP and frailty. 6 (b) at baseline and incident frailty, adjusted for potential confounders.
The relationship between inﬂammation and frailty is complex
since both linearly increase with advancing old age. Both higher
inﬂammatory levels and frailty are associated with several nega-
tive outcomes in the elderly, like higher mortality, hospitalization
rate and co-morbidity onset (Piggott et al., 2015; Sergi et al., 2015;
Zunszain et al., 2013). In cross-sectional studies, the association of
frailty with higher inﬂammation appears to be consistent since both
frail and pre-frail participants showed signiﬁcant higher serum
levels of CRP, TNF-a, IL-6, white blood cells and ﬁbrinogen. Sev-
eral reasons could explain these results. First, frail and pre-frail
participants have a higher presence of concomitant factors like dis-
ability, medical conditions that could increase the inﬂammatory
parameters. Second, as conﬁrmed by our analyses, frail and pre-frail
people (particularly if community-dwelling) are generally more
obese than robust participants, and obesity signiﬁcantly increases
inﬂammatory parameters (Greenberg and Obin, 2006; Solmi et al.,
2015; Veronese et al., 2015). This hypothesis is also in line with the
increase in adiposity observed in frail subjects that seems to affect
also muscular mass (Addison et al., 2014) and indirectly conﬁrmed
by our meta-regression analysis showing that higher differences
in BMI  between frail or pre-frail vs. robust participants moderated
the results regarding serum CRP concentrations. Finally, frail people
seem to have a signiﬁcant reduction in innate immune system, T-
cell activity, antibodies production and increase in mitochondrial
activity with an increase in oxidative stress products, ultimately
leading to an increase in serum inﬂammatory levels (Hubbard and
Woodhouse, 2010; Li et al., 2011).
Conversely, the analyses from our longitudinal studies did not
show any association between higher inﬂammatory levels and the
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nset of frailty. The lack of relationship might be due to the paucity
f data, however, it may  well also indicate that these inﬂammatory
arkers are not associated with a predisposition for developing
railty and may  arise once frailty has set int. Another hypothe-
is is that the longitudinal studies included in our meta-analysis
ncluded a median of 9 baseline potential confounders. Therefore,
n over-adjustment of the analyses could not to be excluded. The
bsence of an univocal operational deﬁnition for frailty, in fact,
akes the development of measurable biomarkers particularly
mportant (Calvani et al., 2015) and if higher inﬂammatory param-
ters are able to predict the onset of frailty could be of importance
ince they are largely diffused worldwide and since higher inﬂam-
atory parameters probably contribute to transitions from frailty
o disability and other negative outcomes (Zaslavsky et al., 2013).
 possible hypothesis for this lack of association is that frail peo-
le are very sensitive to acute and sub-acute diseases that might
ncrease inﬂammatory parameters during follow-up period and
one of the studies included adjusted their analyses for inher-
nt changes in these markers. Clearly, future studies including
hese adjustments are needed to better investigate the poten-
ial role of inﬂammatory parameters in predicting frailty in the
lderly.
The meta-regression analyses identiﬁed some characteristics
f frail and pre-frail participants compared to robust subjects
ould explain the differences in inﬂammatory parameters seen.
n particular, differences in age and BMI  moderated the results
n the comparison between frail vs. pre-frail/robust regarding
RP and IL-6 suggesting an important role of these factors in
he higher inﬂammatory levels found in these subjects com-
ared to robust ones. On the contrary, the deﬁnition of frailty
id not affect our ﬁndings suggest that, independently from the
eﬁnition used, frail people are characterized by a metabolic sig-
ature in which inﬂammation plays a relevant role (Fontana et al.,
013).
The ﬁndings of our study should be interpreted within its lim-
tations. First, we encountered moderate-high heterogeneity in
ost of the cross-sectional analyses. Whilst the Meta-analysis Of
bservational Studies in Epidemiology (MOOSE) guidelines state
eterogeneity is to be expected when analyzing observational data,
e were only partially able to explain the heterogeneity with meta
egression analysis. Second, almost all the studies used the cri-
eria proposed by Fried et al., but this deﬁnition includes only
hysical frailty and does not consider other aspects (for instance
ognitive status), which is of relevance in frailty (Zaslavsky et al.,
013). The focus on physical frailty is not suitable for people with
dvance cognitive decline (e.g. dementia) who may  also be highly
usceptible to frailty. Therefore, future research is also required to
nderstand frailty (considering cognitive status) and inﬂammation
mong people with dementia. Moreover, the frailty phenotype did
ot allow to a better understanding of the underlying contribut-
ng factors to frailty and inﬂammation. Third, the categorization
f people as robust/pre-frail/frail other factors (e.g. differences
n comorbidities) may  explain some of the relationship between
hysical frailty and inﬂammation. Therefore, future studies using
ther deﬁnitions of frailty should attempt to match up frail/pre
rail and robust participants and account for between group differ-
nces in important comorbidities/factors which may  also inﬂuence
nﬂammation. Fourth, all the studies investigating frailty accord-
ng to the deﬁnition of Fried et al. and did not use the original
ersions and instead adapted the frailty criteria which can inﬂu-
nce the quality of the composite score and potentially introduce
ias (Theou et al., 2015). Agreement between modiﬁed criteria with
he primary frailty phenotype, in fact, is generally low-moderate.
owever, the impact of this on our results is unclear. Finally,
nly three longitudinal studies were eligible, with a lack of clar-
ty concerning the results. Therefore, future longitudinal researchh Reviews 31 (2016) 1–8
is required to disentangle the directionality of the inﬂammation
and frailty relationships we observed in our comprehensive cross
sectional analyses. Nonetheless, our meta-analysis is a ﬁrst and
included a large number of studies included and inﬂammatory out-
comes. The data from our cross sectional results were also free
from publication bias and the results indicating greatly increased
levels of CRP and IL-6 had very large fail safe number of studies
(both >1000).
In conclusion, frailty and pre-frailty are associated with higher
inﬂammatory parameters levels, in particular CRP and IL-6. How-
ever, longitudinal studies did not conﬁrm these ﬁndings, suggesting
that other studies are needed to better understand if these inﬂam-
matory markers could be used as potential biomarkers of frailty in
the elderly.
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